European Journal of Radiology, Год журнала: 2024, Номер 171, С. 111314 - 111314
Опубликована: Янв. 13, 2024
To summarize the underlying biological correlation of prognostic radiomics and deep learning signatures in patients with lung cancer evaluate quality available studies.
Язык: Английский
New England Journal of Medicine, Год журнала: 2023, Номер 389(18), С. 1672 - 1684
Опубликована: Окт. 23, 2023
Neoadjuvant or adjuvant immunotherapy can improve outcomes in patients with resectable non–small-cell lung cancer (NSCLC). Perioperative regimens may combine benefits of both to long-term outcomes. Download a PDF the Research Summary. We randomly assigned NSCLC (stage II IIIB [N2 node stage] according eighth edition AJCC Cancer Staging Manual) receive platinum-based chemotherapy plus durvalumab placebo administered intravenously every 3 weeks for 4 cycles before surgery, followed by 12 cycles. Randomization was stratified disease stage (II III) and programmed death ligand 1 (PD-L1) expression (≥1% <1%). Primary end points were event-free survival (defined as time earliest occurrence progressive that precluded surgery prevented completion recurrence [assessed blinded fashion independent central review], from any cause) pathological complete response (evaluated centrally). A total 802 (400 patients) (402 patients). The duration significantly longer than placebo; hazard ratio progression, recurrence, 0.68 (95% confidence interval [CI], 0.53 0.88; P=0.004) at first interim analysis. At 12-month landmark analysis, observed 73.4% who received CI, 67.9 78.1), compared 64.5% 58.8 69.6). incidence greater (17.2% vs. 4.3% final analysis; difference, 13.0 percentage points; 95% 8.7 17.6; P<0.001 analysis data 402 Event-free benefit regardless PD-L1 expression. Adverse events maximum grade occurred 42.4% 43.2% placebo. Data 62 documented EGFR ALK alterations excluded efficacy analyses modified intention-to-treat population. In NSCLC, perioperative neoadjuvant associated alone, safety profile consistent individual agents. (Funded AstraZeneca; AEGEAN ClinicalTrials.gov number, NCT03800134.) QUICK TAKE VIDEO SUMMARYPerioperative Chemoimmunotherapy Lung 02:08
Язык: Английский
Процитировано
271
Current Oncology, Год журнала: 2022, Номер 29(3), С. 1828 - 1839
Опубликована: Март 9, 2022
Lung cancer is the leading cause of death in Canada and a significant morbidity for patients their loved ones. There have been rapid advances preventing, screening treating this disease. Here, we present contemporary review treatment non-small cell lung based on current best practices. The focus to highlight recent data cancer, management with early locally-advanced as well metastatic special incorporation immunotherapy into practice its associated toxicities.
Язык: Английский
Процитировано
175
BMJ, Год журнала: 2022, Номер unknown, С. e069008 - e069008
Опубликована: Март 30, 2022
To determine the effect of introduction low dose computed tomography screening in 2013 on lung cancer stage shift, survival, and disparities diagnosed United States.Quasi-experimental study using Joinpoint modeling, multivariable ordinal logistic regression, Cox proportional hazards modeling.US National Cancer Database Surveillance Epidemiology End Results program database.Patients aged 45-80 years as having non-small cell (NSCLC) between 1 January 2010 31 December 2018.Annual per cent change percentage I NSCLC among patients 45-54 (ineligible for screening) 55-80 (potentially eligible screening), median all cause incidence NSCLC; adjusted odds ratios year-to-year changes likelihood earlier stages disease at diagnosis hazard death before versus after screening.The did not significantly increase from to (from 27.8% 29.4%) then increased 3.9% (95% confidence interval 3.0% 4.8%) year 2014 2018 30.2% 35.5%). In analysis, a patient one lower during time period was 6.2% (multivariable ratio 1.062, 95% 1.048 1.077; P<0.001) higher than 2013. Similarly, survival 15.8 18.1 months), 11.9% (8.9% 15.0%) 19.7 28.2 months). decreased faster compared with (P<0.001). By 2018, predominant non-Hispanic white people living highest income or best educated regions. Non-white those less regions remained more likely have IV diagnosis. Increases detection early US led an estimated 10 100 averted deaths.A recent shift toward coincides improved screening. areas greater deprivation had rates identified, highlighting need efforts access US.
Язык: Английский
Процитировано
93
Science China Life Sciences, Год журнала: 2023, Номер 66(11), С. 2515 - 2526
Опубликована: Апрель 13, 2023
Язык: Английский
Процитировано
80
Cancer Cell, Год журнала: 2023, Номер 41(5), С. 970 - 985.e3
Опубликована: Апрель 20, 2023
Язык: Английский
Процитировано
52
Journal of Thoracic Oncology, Год журнала: 2023, Номер 18(12), С. 1703 - 1713
Опубликована: Июнь 29, 2023
Язык: Английский
Процитировано
42
Cell Communication and Signaling, Год журнала: 2024, Номер 22(1)
Опубликована: Апрель 15, 2024
Abstract Cancer is a major public health problem worldwide with more than an estimated 19.3 million new cases in 2020. The occurrence rises dramatically age, and the overall risk accumulation combined tendency for cellular repair mechanisms to be less effective older individuals. Conventional cancer treatments, such as radiotherapy, surgery, chemotherapy, have been used decades combat cancer. However, emergence of novel fields research has led exploration innovative treatment approaches focused on immunotherapy, epigenetic therapy, targeted multi-omics, also multi-target therapy. hypothesis was based that drugs designed act against individual targets cannot usually battle multigenic diseases like Multi-target therapies, either combination or sequential order, recommended acquired intrinsic resistance anti-cancer treatments. Several studies multi-targeting treatments due their advantages include; overcoming clonal heterogeneity, lower multi-drug (MDR), decreased drug toxicity, thereby side effects. In this study, we'll discuss about drugs, benefits improving recent advances field multi-targeted drugs. Also, we will study performed clinical trials using therapeutic agents treatment.
Язык: Английский
Процитировано
34
Seminars in Nuclear Medicine, Год журнала: 2025, Номер unknown
Опубликована: Март 1, 2025
Lung cancer remains one of the most prevalent cancers globally and leading cause cancer-related deaths, accounting for nearly one-fifth all fatalities. Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography ([18F]FDG PET/CT) plays a vital role in assessing lung managing disease progression. While traditional PET/CT imaging relies on qualitative analysis basic quantitative parameters, radiomics offers more advanced approach to analyzing tumor phenotypes. Recently, has gained attention its potential enhance prognostic diagnostic capabilities [18F]FDG various cancers. This review explores expanding PET/CT-based radiomics, particularly when integrated with artificial intelligence (AI), cancer, especially non-small cell (NSCLC). We how AI improve diagnostics, staging, subtype identification, molecular marker detection, which influence treatment decisions. Additionally, we address challenges clinical integration, such as protocol standardization, feature reproducibility, need extensive prospective studies. Ultimately, hold great promise enabling personalized effective treatments, potentially transforming management.
Язык: Английский
Процитировано
2
Cancer Investigation, Год журнала: 2022, Номер 41(1), С. 12 - 24
Опубликована: Авг. 29, 2022
The therapeutic landscape of lung cancer treatment is changing rapidly, and new data was presented at the recently concluded American Society Clinical Oncology 2022 (ASCO22) meeting. We highlight studies clinical relevance that represent significant updates in current management non-small cell (SCLC) small (NSCLC). summarize early-stage NSCLC, mutated non-mutated advanced NSCLC as well (SCLC), discuss these advances context standard care.
Язык: Английский
Процитировано
65
Cancers, Год журнала: 2022, Номер 14(21), С. 5430 - 5430
Опубликована: Ноя. 4, 2022
In NSCLC, KRAS mutations occur in up to 30% of all cases, most frequently at codon 12 and 13. have been linked adenocarcinoma histology, positive smoking history, Caucasian ethnicity, although differences described across mutational variants subtypes. often concur with other molecular alterations, notably TP53, STK11, KEAP1, which could play an important role treatment efficacy patient outcomes. For many years, considered undruggable mainly due a high toxicity profile low specificity compounds. Sotorasib adagrasib are novel inhibitors that recently gained FDA approval for pre-treated mutant NSCLC patients, molecules such as GDC-6036 currently being investigated promising results. Despite their approval, the these drugs is lower than expected progression among responders has reported. Mechanisms acquired resistance anti-KRAS typically involves either on target secondary (e.g., G12, G13, Q61H, R68S, H95, Y96C, V8L) or off-target alterations. Ongoing trials evaluating strategies implementing overcoming Finally, immune-checkpoint still needs be completely assessed responses anti-PD-1/PD-L1 agents may strongly depend concomitant mutations.
Язык: Английский
Процитировано
44